BioCryst stock trades ahead of November 4 results

Company: BioCryst Pharmaceuticals, Inc.
ISIN: US09058V1035
Ticker: BCRX
Lang & Schwarz quote: EUR 7.57 on November 3, 2026, at 10:20 p.m. CET
Next event: Third-quarter 2026 results on November 4, 2026

Published on 11/03/2026 at 22:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioCryst stock traded at EUR 7.57 in Berlin late Tuesday. BioCryst Pharmaceuticals is due to release third-quarter results on November 4.

BioCryst awaits quarterly results

BioCryst Pharmaceuticals is scheduled to publish its third-quarter 2026 results on November 4.
The company focuses on oral and injectable therapies for hereditary angioedema and other rare diseases.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals stock traded at EUR 7.57 on Lang & Schwarz at 10:20 p.m. CET on Tuesday, November 3, 2026, according to the real-time quote of BioCryst Pharmaceuticals stock.

Results Due November 4

BioCryst Pharmaceuticals is scheduled to report its third-quarter 2026 financial results on Wednesday, November 4. The company has scheduled its conference call for 8:30 a.m. Eastern Time, according to the BioCryst investor relations page.

Rare Disease Portfolio

The biotechnology company develops oral small-molecule and injectable protein therapies for hereditary angioedema and other rare diseases. Its commercial portfolio includes ORLADEYO, an oral, once-daily plasma kallikrein inhibitor.